The partnership between Propeller and Novartis will use the digital device to record compliance data from the inhaler and provide the data to patients and their physicians.
This marks Propeller’s fifth major pharma partnership. With existing agreements with Boehringer Ingelheim and GSK, Propeller’s collaboration with Novartis rounds out the portfolio to include three of the top five respiratory pharma companies for asthma and COPD.
“This represents a bring-your-own-device strategy, as we think about Propeller as a software solution,” Propeller CEO David Van Sickle told MobiHealthNews. “This is just one more of the major pharma companies who are now using Propeller as a common digital interface.”
Other stories from MobiHealthNews:
- Remote patient monitoring market grew by 44 percent in 2016, report says
- Study: Workplace wellness programs focused on cardiovascular health may reduce prevalence of disease
- Pharmaceutical companies and digital health startups: It’s time to get together
This story first appeared in the Klick Wire, delivered 7AM every Monday. Sign up to get the Wire today!